Search Results 911-920 of 17100 for monoclonal antibody

1. A Study to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors - Mayo Clinic

   Participant has received immune therapy (monoclonal antibody therapy, checkpoint inhibitors) within 4 weeks of lymphodepletion. Participant had major ...

2. Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) - Mayo Clinic

   No history of severe allergic reactions to monoclonal antibodies. Female ... Hepatitis C as indicated by anti-hepatitis C antibody positivity; if a participant is ...

3. Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors - Mayo Clinic

   ... monoclonal antibodies. Patients must not have received prior treatment with a VEGFR tyrosine kinase inhibitor. Except for Cohort D (MSS mCRC), patients must ...

4. Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary - Mayo Clinic

   ... monoclonal antibody or hypersensitivity to pembrolizumab or any of its excipients. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks ...

5. Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Monoclonal plasma cells in the bone marrow ≥ 10% at ... Subject has known allergies, hypersensitivity, or intolerance to VELCADE, monoclonal antibodies ...

6. Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma - Mayo Clinic

   ... monoclonal antibody specific for the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP), in patients whose asthma remained uncontrolled ...

7. Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) - Mayo Clinic

   Prior monoclonal antibody within 4 weeks prior to study Day 1 (2 weeks for RS participants) or who has not recovered (i.e. ≤ Grade 1 or at baseline) from ...

8. Diseases and Conditions that Start with M - Mayo Clinic

   Monoclonal gammopathy of undetermined significance (MGUS) ... MOG antibody-associated disorder. See. Myelin ... Monoclonal gammopathy of undetermined significance ( ...

9. Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer - Mayo Clinic

   0) hypersensitivity reactions to monoclonal antibodies, or history of anaphylaxis. Vaccination within 28 days of the first dose of study drugs and while on ...

10. Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma - Mayo Clinic

    Monoclonal antibody; at least three half-lives since the last dose; Non-antibody immunotherapy (e.g., tumor vaccine); at least 42 days since last dose ...